Clinical Trial Update: A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase II study of Rivoceranib for recurrent or metastatic olfactory neuroblastoma has been withdrawn from the registry; no results are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Olfactory Neuroblastoma

Drugs mentioned

• Rivoceranib (rivoceranib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma | Phase 2 | Status: WITHDRAWN